Inactive Instrument
CardieX Limited Share Price OTC Markets
Stocks
CDEX.F
AU0000015729
Advanced Medical Equipment & Technology
OTC Markets Traded| Market Cap | 19.01M 13.64M 11.76M 11.02M 10.06M 18.95M 1.3B 131M 51.02M 658M 51.22M 50.1M 2.18B | P/E 2024 |
-2.06x | P/E 2025 | -0.78x |
|---|---|---|---|---|---|
| Enterprise Value | 20.21M 14.5M 12.5M 11.72M 10.7M 20.15M 1.39B 139M 54.23M 700M 54.45M 53.26M 2.32B | EV / Sales 2024 |
1.87x | EV / Sales 2025 | 3.83x |
| Free-Float |
68.31% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript : CardieX Limited
| 17/07/24 | CardieX : Annual Report 202 | PU |
| 15/05/24 | CardieX : Stock Information | PU |
| 04/07/22 | CardieX : Application for quotation of securities - CDX | PU |
| 29/04/22 | CardieX : March Quarterly Activities Report | PU |
| 12/04/22 | CardieX : subsidiary files key regulatory submission for CONNEQT companion app | PU |
| Manager | Title | Age | Since |
|---|---|---|---|
Craig R. Cooper
CEO | Chief Executive Officer | - | - |
Sanjeev Bhavnani
CTO | Chief Tech/Sci/R&D Officer | - | 29/02/2024 |
Steven Kesten
CTO | Chief Tech/Sci/R&D Officer | 67 | - |
| Director | Title | Age | Since |
|---|---|---|---|
R. Nelson
BRD | Director/Board Member | 69 | 12/11/2015 |
Craig R. Cooper
BRD | Director/Board Member | - | 30/11/2017 |
Niall Cairns
CHM | Chairman | 62 | 26/02/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +166.67% | - | - | 9.09M | |
| -1.35% | -1.13% | +26.27% | +12.02% | 230B | |
| +0.18% | -1.27% | +4.98% | -18.16% | 152B | |
| +1.51% | -1.64% | -21.28% | +20.04% | 132B | |
| +0.36% | -7.01% | -55.60% | -14.34% | 67.88B | |
| +0.29% | +0.47% | +10.90% | +15.91% | 52B | |
| +0.66% | -1.69% | -16.47% | -14.35% | 51.05B | |
| -2.44% | -3.25% | +22.43% | +26.08% | 43.38B | |
| -1.56% | +0.97% | +37.41% | +44.08% | 40.74B | |
| +1.94% | +3.81% | -12.45% | +46.61% | 34.67B | |
| Average | -0.04% | -0.84% | -0.42% | +13.10% | 89.25B | |
| Weighted average by Cap. | -0.14% | -1.29% | +2.51% | +7.86% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 12.81M 9.19M 7.92M 7.43M 6.78M 12.77M 879M 88.12M 34.38M 444M 34.51M 33.76M 1.47B | 6.05M 4.34M 3.74M 3.51M 3.2M 6.03M 415M 41.63M 16.24M 210M 16.3M 15.95M 695M |
| Net income | -6.77M -4.85M -4.18M -3.92M -3.58M -6.74M -464M -46.53M -18.15M -234M -18.22M -17.83M -776M | -18.19M -13.05M -11.25M -10.55M -9.63M -18.14M -1.25B -125M -48.82M -630M -49.01M -47.94M -2.09B |
| Net Debt | 3.35M 2.4M 2.07M 1.94M 1.77M 3.34M 229M 23.01M 8.98M 116M 9.01M 8.82M 384M | 1.2M 860K 741K 695K 634K 1.19M 82.18M 8.24M 3.22M 41.48M 3.23M 3.16M 138M |
Employees
-
